Top

BMC Nephrology

Published in:

Open Access 01-12-2019 | Intoxication | Case report

Treatment of lead and arsenic poisoning in anuric patients – a case report and narrative review of the literature

Authors: Chun-Yuan Hsiao, Chip Gresham, Mark R. Marshall

Published in: BMC Nephrology | Issue 1/2019

Abstract

Background

Heavy metal poisoning can cause debilitating illness if left untreated, and its management in anuric patients poses challenges. Literature with which to guide clinical practice in this area is rather scattered.

Case presentation

We present a case of symptomatic lead and arsenic poisoning from use of Ayurvedic medicine in a 28-year-old man with end-stage kidney disease on chronic hemodialysis. We describe his treatment course with chelating agents and extracorporeal blood purification, and review the relevant literature to provide general guidance.

Conclusion

Cumulative clinical experience assists in identifying preferred chelators and modalities of extracorporeal blood purification when managing such patients. However, a larger body of real-world or clinical trial evidence is necessary to inform evidence-based guidelines for the management of heavy metal poisoning in anuric patients.

Marafante E, Vahter M, Norin H, Envall J, Sandstrom M, Christakopoulos A, Ryhage R. Biotransformation of dimethylarsinic acid in mouse, hamster and man. J Appl Toxicol. 1987;7(2):111–7.PubMedCrossRef

Abadin H, Ashizawa A, Stevens YW, Llados F, Diamond G, Sage G, Citra M, Quinones A, Bosch SJ, Swarts SG. Toxicological Profile for Lead. Atlanta: Agency for Toxic Substances and Disease Registry; 2007:24049859.

Klaassen CD. Heavy metals and heavy-metal antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics 11th Ed. United States: McGraw-Hill; 2006. https://doi.org/10.1036/0071422803.

Aposhian HV. DMSA and DMPS--water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol. 1983;23:193–215.PubMedCrossRef

Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745–88.PubMedCrossRefPubMedCentral

Chisolm JJ Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Toxicol Clin Toxicol. 1992;30(4):493–504.PubMedCrossRef

Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond). 1996;46(1):41–8.CrossRef

Vaziri ND, Upham T, Barton CH. Hemodialysis clearance of arsenic. Clin Toxicol. 1980;17(3):451–6.PubMedCrossRef

Kruszewska S, Wiese M, Kolacinski Z, Mielczarska J. The use of haemodialysis and 2,3 propanesulphonate (DMPS) to manage acute oral poisoning by lethal dose of arsenic trioxide. Int J Occup Med Environ Health. 1996;9(2):111–5.PubMed

10.

Mathieu D, Mathieu-Nolf M, Germain-Alonso M, Neviere R, Furon D, Wattel F. Massive arsenic poisoning--effect of hemodialysis and dimercaprol on arsenic kinetics. Intensive Care Med. 1992;18(1):47–50.PubMedCrossRef

11.

Zilker TH, Felgenhauer N, Pfab R, Drasch G, Roos G. Little effect of haemodialysis and CAVHDF on the elimination of arsenic compared to DMPS treatment. J Toxicol Clin Toxicol. 1999;37:400–1.

12.

Thomson RM, Parry GJ. Neuropathies associated with excessive exposure to lead. Muscle Nerve. 2006;33(6):732–41.PubMedCrossRef

13.

Zhang X, Cornelis R, de Kimpe J, Mees L, Lameire N. Study of arsenic-protein binding in serum of patients on continuous ambulatory peritoneal dialysis. Clin Chem. 1998;44(1):141–7.PubMed

14.

Lai MW, Boyer EW, Kleinman ME, Rodig NM, Ewald MB. Acute arsenic poisoning in two siblings. Pediatrics. 2005;116(1):249–57.PubMedCrossRef

15.

Zhang X, Cornelis R, Mees L, Vanholder R, Lameire N. Chemical speciation of arsenic in serum of uraemic patients. Analyst. 1998;123(1):13–7.PubMedCrossRef

16.

Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Dart RC, Aposhian MM. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97(1-3):23–38.PubMedCrossRef

17.

Osterloh J, Becker CE. Pharmacokinetics of CaNa2EDTA and chelation of lead in renal failure. Clin Pharmacol Ther. 1986;40(6):686–93.PubMedCrossRef

18.

Tillotson JA, Boswell G, Kincannon L, Speckman CL. The biological fate of 14C-dimercaptosuccinic acid in monkeys and rabbits. Mil Med. 1989;154(9):444–9.PubMedCrossRef

19.

Maiorino RM, Xu ZF, Aposhian HV. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther. 1996;277(1):375–84.PubMed

20.

Babiker MM. Binding of [51Cr] ethylenediaminetetraacetate to proteins of human plasma. J Physiol. 1986;374:117–22.PubMedCrossRefPubMedCentral

21.

Maiorino RM, Akins JM, Blaha K, Carter DE, Aposhian HV. Determination and metabolism of dithiol chelating agents: X. in humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther. 1990;254(2):570–7.PubMed

22.

Howland MA. Antidotes in Depth - Dimercaprol (British Anti-Lewisite or BAL). In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, editors. Goldfrank's Toxicologic Emergencies, 8th Ed. New York: McGraw-Hill Education - Europe; 2006. p. 1266–8. https://www.bookdepository.com/Goldfranks-Toxicologic-Emergencies-Eighth-Edition-Lewis-R-Goldfrank/9780071437639.

23.

de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Des. 2002;8(15):1391–403.PubMedCrossRef

24.

Giberson A, Vaziri ND, Mirahamadi K, Rosen SM. Hemodialysis of acute arsenic intoxication with transient renal failure. Arch Intern Med. 1976;136(11):1303–4.PubMedCrossRef

25.

Blythe D, Joyce DA. Clearance of arsenic by haemodialysis after acute poisoning with arsenic trioxide. Intensive Care Med. 2001;27(1):334.PubMedCrossRef

26.

Smith SB, Wombolt DG, Venkatesan R. Results of hemodialysis & hemoperfusion in the treatment of acute arsenic ingestion. Clin Exp Dial Apheresis. 1981;5(4):399–404.PubMedCrossRef

27.

Levin-Scherz JK, Patrick JD, Weber FH, Garabedian C Jr. Acute arsenic ingestion. Ann Emerg Med. 1987;16(6):702–4.PubMedCrossRef

28.

Fesmire FM, Schauben JL, Roberge RJ. Survival following massive arsenic ingestion. Am J Emerg Med. 1988;6(6):602–6.PubMedCrossRef

29.

Hantson P, Haufroid V, Buchet JP, Mahieu P. Acute arsenic poisoning treated by intravenous dimercaptosuccinic acid (DMSA) and combined extrarenal epuration techniques. J Toxicol Clin Toxicol. 2003;41(1):1–6.PubMedCrossRef

30.

Adam B. DMPS und Dimercaprol in der Therapie der akuten Arsenintoxikation. In: Dissertation. Germany: Technical University of Munich; 2004. https://mediatum.ub.tum.de/doc/602356/602356.pdf.

31.

Aposhian HV, Carter DE, Hoover TD, Hsu CA, Maiorino RM, Stine E. DMSA, DMPS, and DMPA--as arsenic antidotes. Fundam Appl Toxicol. 1984;4(2 Pt 2):S58–70.PubMedCrossRef

32.

Guha Mazumder DN, Ghoshal UC, Saha J, Santra A, De BK, Chatterjee A, Dutta S, Angle CR, Centeno JA. Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. J Toxicol Clin Toxicol. 1998;36(7):683–90.PubMedCrossRef

33.

Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. Clin Toxicol (Phila). 2009;47(7):617–31.CrossRef

34.

Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int. 2008;74(10):1327–34.PubMedCrossRef

35.

Shalkham AS, Kirrane BM, Hoffman RS, Goldfarb DS, Nelson LS. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis. 2006;48(2):239–41.PubMedCrossRef

36.

Sheabar FZ, Yannai S, Taitelman U. Efficiency of arsenic clearance from human blood in vitro and from dogs in vivo by extracorporeal complexing haemodialysis. Pharmacol Toxicol. 1989;64(4):329–33.PubMedCrossRef

37.

Smith HD, King LR, Margolin EG. Treatment of Lead Encephalopathy. The Combined Use of Edetate and Hemodialysis. Am J Dis Child. 1965;109:322–4.PubMedCrossRef

38.

Mehbod H. Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA. 1967;201(12):972–4.PubMedCrossRef

39.

Pedersen RS. Lead poisoning treated with haemodialysis. Scand J Urol Nephrol. 1978;12(2):189–90.PubMedCrossRef

40.

Roger SD, Crimmins D, Yiannikas C, Harris DC. Lead intoxication in an anuric patient: management by intraperitoneal EDTA. Aust NZ J Med. 1990;20(6):814–7.CrossRef

41.

Kessler M, Durand PY, Hestin D, Cao Huu T, Renoult E, Prenat E, Chanliau J, Kaminski P, Duc M. Elevated body lead burden from drinking water in end-stage chronic renal failure. Nephrol Dial Transplant. 1995;10(9):1648–53.PubMed

42.

Kessler M, Durand PY, Huu TC, Royer-Morot MJ, Chanliau J, Netter P, Duc M. Mobilization of lead from bone in end-stage renal failure patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 1999;14(11):2731–3.PubMedCrossRef

43.

Barats MS, Gonick HC, Rothenberg S, Balabanian M, Manton WI. Severe lead-induced peripheral neuropathy in a dialysis patient. Am J Kidney Dis. 2000;35(5):963–8.PubMedCrossRef

44.

Roberts DM, Singer RF. Lead mobilization study and the clearance of intravenous CaNa2EDTA in a patient with end-stage renal failure on hemodialysis. J Clin Pharmacol. 2012;52(1):110–3.PubMedCrossRef

45.

Chisolm JJ Jr. Treatment of acute lead intoxication--choice of chelating agents and supportive therapeutic measures. Clin Toxicol. 1970;3(4):527–40.PubMedCrossRef

46.

Lee BK, Schwartz BS, Stewart W, Ahn KD. Provocative chelation with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med. 1995;52(1):13–9.PubMedCrossRefPubMedCentral

47.

Tandon SK, Singh S, Jain VK. Efficacy of combined chelation in lead intoxication. Chem Res Toxicol. 1994;7(5):585–9.PubMedCrossRef

48.

Hruby K, Donner A. 2,3-Dimercapto-1-propanesulphonate in heavy metal poisoning. Med Toxicol Adverse Drug Exp. 1987;2(5):317–23.PubMed

49.

Chisolm JJ Jr, Thomas DJ. Use of 2,3-dimercaptopropane-1-sulfonate in treatment of lead poisoning in children. J Pharmacol Exp Ther. 1985;235(3):665–9.PubMed

50.

Moore DF, O'Callaghan CA, Berlyne G, Ogg CS, Davies HA, House IM, Henry JA. Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS). J Neurol Neurosurg Psychiatry. 1994;57(9):1133–5.PubMedCrossRefPubMedCentral

51.

Wax PM, Thornton CA. Recovery from severe arsenic-induced peripheral neuropathy with 2,3-dimercapto-1-propanesulphonic acid. J Toxicol Clin Toxicol. 2000;38(7):777–80.PubMedCrossRef

52.

Aposhian HV, Arroyo A, Cebrian ME, del Razo LM, Hurlbut KM, Dart RC, Gonzalez-Ramirez D, Kreppel H, Speisky H, Smith A, et al. DMPS-arsenic challenge test. I: increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J Pharmacol Exp Ther. 1997;282(1):192–200.PubMed

53.

Guha Mazumder DN, De BK, Santra A, Ghosh N, Das S, Lahiri S, Das T. Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. J Toxicol Clin Toxicol. 2001;39(7):665–74.PubMedCrossRef

Title: Treatment of lead and arsenic poisoning in anuric patients – a case report and narrative review of the literature
Authors: Chun-Yuan Hsiao
Chip Gresham
Mark R. Marshall
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Intoxication
Renal Replacement Procedures
Encephalopathy
Published in: BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-019-1561-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of lead and arsenic poisoning in anuric patients – a case report and narrative review of the literature

Abstract

Background

Case presentation

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Point-of-care ultrasound in Management for Dyspneic Uremic Patients: a case report

Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3–5 chronic kidney disease: a prospective observational study

Impact of blood glucose levels on the accuracy of urinary N-acety-β-D-glucosaminidase for acute kidney injury detection in critically ill adults: a multicenter, prospective, observational study

Urinary cell-free mitochondrial and nuclear deoxyribonucleic acid correlates with the prognosis of chronic kidney diseases

Investigation of the variants at the binding site of inflammatory transcription factor NF-κB in patients with end-stage renal disease

Saliva for assessing creatinine, uric acid, and potassium in nephropathic patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page